Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 50%GRADE not reported 0 · 0%Very low 3 · 50%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroids

Proportion of participants achieving control of inflammation (higher number of events is better) · NIIPPU

It is very uncertain whether non‐biologic disease‐modifying antirheumatic drugs (DMARDs) changes proportion of participants achieving control of inflammation (higher… compared with steroid (very low certainty).

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
RR 2.81 [1.1, 7.17]
1 study · 41 participants
Very low

Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroids

Change in BCVA (lower logMAR indicate better vision) · NIIPPU

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 82 participants
Very low

Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroids

Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU

The review found no eligible studies for this question.

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroids

Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU

The review found no eligible studies for this question.

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroids

Proportion of participants achieving steroid‐sparing control (higher number of events is better) · NIIPPU

The review found no eligible studies for this question.

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Non‐biologic disease‐modifying antirheumatic drugs (DMARDs) vs steroids

Proportion of participants experiencing complications or requiring cessation of medication (lower number of events is better) · NIIPPU

1 finding from 1 review

Non‐biologic, steroid‐sparing therapies for non‐infectious intermediate, posterior, and panuveitis in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low